174 related articles for article (PubMed ID: 38582965)
21. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
22. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
23. shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer.
Zhang H; Yao J; Ajmal I; Farooq MA; Jiang W
Front Immunol; 2024; 15():1369406. PubMed ID: 38835760
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
25. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
26. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Front Immunol; 2021; 12():738456. PubMed ID: 34721401
[TBL] [Abstract][Full Text] [Related]
27. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
28. Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors.
Luo Q; Napoleon JV; Liu X; Zhang B; Zheng S; Low PS
Mol Cancer Res; 2022 May; 20(5):823-833. PubMed ID: 35135862
[TBL] [Abstract][Full Text] [Related]
29. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.
Tantalo DG; Oliver AJ; von Scheidt B; Harrison AJ; Mueller SN; Kershaw MH; Slaney CY
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035114
[TBL] [Abstract][Full Text] [Related]
30. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.
Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454
[TBL] [Abstract][Full Text] [Related]
31. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
32. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells.
Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ
Front Immunol; 2021; 12():782448. PubMed ID: 34868059
[TBL] [Abstract][Full Text] [Related]
34. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
35. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
36. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
37. Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response.
Liu C; Qi T; Milner JJ; Lu Y; Cao Y
Front Immunol; 2021; 12():748768. PubMed ID: 34691062
[TBL] [Abstract][Full Text] [Related]
38. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
39. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
40. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8
Seo H; Chen J; González-Avalos E; Samaniego-Castruita D; Das A; Wang YH; López-Moyado IF; Georges RO; Zhang W; Onodera A; Wu CJ; Lu LF; Hogan PG; Bhandoola A; Rao A
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12410-12415. PubMed ID: 31152140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]